Alpha-1 Antitrypsin Deficiency clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18-80
This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.
Sacramento, California and other locations
Our lead scientists for Alpha-1 Antitrypsin Deficiency research studies include Brooks Kuhn, MD.